ING Group’s Nektar Therapeutics NKTR Stock Holding History

ING Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.2M	Hold	100,000	–	–	0.04%	236
2025 Q4	$4.23M	Buy	+100,000	New	+$5.6M	0.03%	302
2019 Q4	–	Sell	-729	Closed	-$199K	–	513
2019 Q3	$199K	Buy	+729	New	+$267K	0.01%	468
2019 Q2	–	Sell	-689	Closed	-$347K	–	809
2019 Q1	$347K	Buy	+689	New	+$408K	0.01%	564
2018 Q4	–	Sell	-342	Closed	-$313K	–	793
2018 Q3	$313K	Buy	+342	New	+$292K	0.01%	646

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ING Group's NKTR Position: Q1 2026 in Review

ING Group held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 100,000 shares worth $7.2M. The position accounts for 0.04% of the portfolio, ranked #236.

ING Group first reported a position in NKTR in Q3 2018 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

ING Group held 100,000 shares of Nektar Therapeutics worth $7.2M as of Q1 2026.
ING Group left its Nektar Therapeutics share count unchanged in Q1 2026.
Nektar Therapeutics made up 0.04% of ING Group's portfolio in Q1 2026, its #236 holding.
ING Group first reported a position in Nektar Therapeutics in Q3 2018 and has held it in 5 quarters since.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on ING Group's 13F filing for Q1 2026, filed 11 May 2026.